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Abstract
Experimental cerebral malaria (ECM) is a severe complication of Plasmodium berghei 
ANKA (PbA) infection in mice, characterized by CD8+ T- cell accumulation within the 
brain. Whilst the dynamics of CD8+ T- cell activation and migration during extant pri-
mary PbA infection have been extensively researched, the fate of the parasite- specific 
CD8+ T cells upon resolution of ECM is not understood. In this study, we show that 
memory OT- I cells persist systemically within the spleen, lung and brain following 
recovery from ECM after primary PbA- OVA infection. Whereas memory OT- I cells 
within the spleen and lung exhibited canonical central memory (Tcm) and effector 
memory (Tem) phenotypes, respectively, memory OT- I cells within the brain post- 
PbA- OVA infection displayed an enriched CD69+CD103− profile and expressed low 
levels of T- bet. OT- I cells within the brain were excluded from short- term intravascu-
lar antibody labelling but were targeted effectively by longer- term systemically admin-
istered antibodies. Thus, the memory OT- I cells were extravascular within the brain 
post- ECM but were potentially not resident memory cells. Importantly, whilst memory 
OT- I cells exhibited strong reactivation during secondary PbA- OVA infection, prevent-
ing activation of new primary effector T cells, they had dampened reactivation during 
a fourth PbA- OVA infection. Overall, our results demonstrate that memory CD8+ T 
cells are systemically distributed but exhibit a unique phenotype within the brain post- 
ECM, and that their reactivation characteristics are shaped by infection history. Our 
results raise important questions regarding the role of distinct memory CD8+ T- cell 
populations within the brain and other tissues during repeat Plasmodium infections.
K E Y W O R D S
brain, CD8+ T cell, cerebral malaria, immune memory
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INTRODUCTION
Human cerebral malaria (HCM) is a major cause of mor-
tality following Plasmodium falciparum infection, respon-
sible for approximately 300 000 deaths annually [1]. The 
Plasmodium berghei ANKA (PbA) model of experimental 
cerebral malaria (ECM) has been extensively utilized to 
study the pathogenesis of malaria- induced neuropathol-
ogy (reviewed [2, 3]). ECM is a multifactorial condition 
characterized by wide- spread disruption to the blood– 
brain barrier with resultant vasogenic oedema and brain 
swelling, significant cerebrovascular congestion and 
haemostasis, cerebral haemorrhaging and parenchymal 
pathologies, including axonal injury [4]. The pathophysi-
ology of ECM is complex, and the spatiotemporal sequence 
of events underlying its genesis remains incompletely un-
derstood; however, accumulation of parasitized red blood 
cells (pRBC) and leucocytes within (and around) the brain 
vasculature network appears to be important events in the 
development of the syndrome [2, 3]. Specifically, a pivotal 
role for CD8+ T cells in development and progression of 
the ECM syndrome has been identified [5, 6].
During primary PbA infection in ECM- susceptible 
strains of mice, such as C57BL/6 mice, pathogenic parasite- 
specific CD8+ T cells are primed in the spleen by cross- 
presenting CD8+ Clec9a+ DCs [7, 8]. The activated CD8+ 
T cells then migrate to the brain in a CXCR3- CXCL10- 
dependent manner and form long- lasting cognate inter-
actions with parasite antigen cross- presenting endothelial 
cells, with CXCL10 playing an additional pathological 
role in the brain by stabilizing the binding of CD8+ T cells 
with the endothelial cells [9– 14]. IFN- γ plays an important 
role in ECM pathogenesis by promoting endothelial cell 
cross presentation, MHC- class I expression and CXCL10 
production within the brain, facilitating CD8+ T- cell entry 
and retention in the brain [10, 11, 15, 16]. Following in-
teraction with parasite- cross- presenting endothelial cells, 
CD8+ T cells mediate disruption of the blood brain barrier 
through Perforin and Granzyme B (GrB) production [17– 
19]. Notably, potential roles for CD8+ T cells in HCM has 
recently been described, with CD8+ T cells found in simi-
lar numbers in the brains during fatal HCM as is observed 
in ECM [20, 21]. Moreover, CD8+ T cells appear to degran-
ulate and release GrB proximal with brain endothelial cells 
in HCM [21], and the proportions of CD8+ T cells produc-
ing GrB were significantly higher in children with severe 
malaria than in those with uncomplicated malaria [22].
Whilst ECM is generally a fatal condition, it can be 
treated, suboptimally, by the administration of antimalar-
ial drugs [23, 24]. How the brain recovers following an ep-
isode of ECM is poorly understood. In particular, whether 
parasite- specific pathogenic CD8+ T cells are retained or 
operate an enhanced immune surveillance programme 
within the brain post- ECM, compared with other affected 
tissue sites such as the lung, has yet to be examined. Of 
relevance, conflicting studies have shown that systemic 
infections may lead to short- term CD8+ T- cell immuno-
surveillance or long- term tissue- resident memory (Trm) 
CD8+ T- cell responses in the brain [25, 26]. Moreover, Trm 
CD8+ T cells, characterized by the expression of the c- type 
lectin CD69 and the integrin CD103, have been observed 
to reside within the brain following various cerebral in-
fections [27– 32]. Interestingly, brain- resident memory 
CD8+CD103+ T cells exhibit a unique gene signature as 
compared with other memory CD8+ T- cell populations 
within different tissue sites [27, 29], which is consistent 
with the model whereby intracerebral CD8+ T cells re-
ceive imprinting upon entry into the brain, promoting 
specialized functions [33].
In this study, we have directly investigated the distri-
bution and fate of parasite- specific CD8+ T cells following 
an episode of ECM. We show that memory CD8+ T cells 
are widely spread following drug treatment of ECM, in-
cluding in the brain, and that intracerebral memory CD8+ 
T cells exhibit a distinct CD69+ CD103− memory pheno-
type compared with memory cells in the spleen and lung. 
Importantly, we demonstrate that memory CD8+ T cells re-
activate very strongly and dominate the splenic and intra-
cerebral CD8+ T- cell responses during secondary challenge 
PbA infection, to the exclusion of new effector CD8+ T cells. 
However, we also reveal that memory CD8+ T- cell reactiva-
tion and pathogenicity is significantly reduced following 
multiple repetitive PbA infections, indicating that memory 
CD8+ T- cell characteristics are not stably imprinted upon 
parasite re- exposure. Combined, our results demonstrate 
that memory CD8+ T cells are maintained with apparent 
tissue- specific imprinting post- PbA infection, and that the 
regulation of memory CD8+ T- cell reactivation is a key 
event governing the outcome of repeat PbA infections.
MATERIALS AND METHODS
Ethics
All animal work was approved by the University of 
Manchester Animal Procedures and Ethics committee 
and was performed in accordance with the UK Home 
Office (HO) Animals (Scientific Procedures) Act 1986 
(HO Project licences 70/7293 and P8829D3B4).
Parasites and infections
C57BL/6 mice were purchased from Charles River, UK. 
CD45·1+/− OT- I mice and CD45·1+/+ OT- I mice were 
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generated and bred at the University of Manchester by 
crossing CD45·1+ (Pep3) mice with RAG- 1 OT- I mice to 
F1 and F2 generations, respectively. Resultant mice were 
genotyped by assessing CD45·1/CD45·2 expression and 
presence of the OT- I TCR (Vα2 and Vβ5) by flow cytom-
etry. Mice were maintained in individual ventilated cages 
at the University of Manchester.
Cryopreserved transgenic PbA parasites expressing ova 
epitopes (OVA323– 339[KISQAVHAAHAEINEAG]) and GFP 
under control of the P. berghei elongation factor (EF)- 1a 
promoter (PbTg parasites referred to in this study as PbA- 
OVA) [34], kindly provided by Professor Heath, University 
of Melbourne, were thawed and passaged once through 
C57BL/6 mice. Experimental animals were infected in-
travenously (i.v.) with 1 × 104 pRBC. PbA- OVA parasites 
were maintained under pyrimethamine selection in vivo 
in both passage and experimental mice, as previously de-
scribed [34]. Peripheral parasite levels were assessed every 
2nd day of infection by examination of Giemsa- stained 
thin blood smears.
Animals were drug- cured by six consecutive daily in-
traperitoneal (i.p.) injections of chloroquine and artesu-
nate (both 30 mg/kg), commenced when animals showed 
prodromal signs of ECM, typically on day 6 of infection, as 
previously described [23, 24]. In some experiments, ani-
mals were re- infected on day 60 post- infection with 1 × 104 
PbA- OVA pRBCs, as described above. In specific experi-
ments, animals were injected i.p. with 250  μg anti- CD8 
mAb (clone 53- 6·72) or control rat IgG2a Ab for two con-
secutive days on day 60 post- primary infection to examine 
the capacity of systemically administered anti- CD8α mAb 
to target memory CD8+ T cells, or were injected on days 
−1, 1, 3, 5 and 7 of secondary challenge infection to ex-
amine the role of blood- accessible memory CD8+ T cells 
in promoting ECM during challenge infection. In other 
experiments, animals were injected i.v. with 3  μg anti- 
CD45- FITC (30- F11) on day 60 post- infection, and were 
culled after 3 min to examine in vivo labelling of intravas-
cular cells [35]. Antibodies for in vivo administration from 
BioXcell (West Lebanon, NH). To generate repeatedly in-
fected mice, mice were treated with antimalarial drugs 
during primary infection, as described above, when they 
exhibited prodromal signs of ECM and this cycle was re-
peated up to three times, with a minimum of 30 days be-
tween clearance of parasites and re- infection [23].
ECM was graded as previously described [36]: 1 = no 
signs; 2 = ruffled fur/and or abnormal posture; 3 = leth-
argy; 4  =  reduced responsiveness to stimulation and/
or ataxia and/or respiratory distress/hyperventilation; 
5  =  prostration and/or paralysis and/or convulsions. 
Stages 2 and 3 were classified as prodromal ECM, and 
stages 4– 5 were classified as ECM. PbA- infected mice 
were euthanized when they reached stage 4/5.
Flow cytometry
Spleens were removed and single- cell suspensions cre-
ated by homogenizing the tissue through a 70- µm cell 
sieve (BD Biosciences). Brains and lungs were isolated 
from mice following intracardiac perfusion with PBS. 
Gentle intracardiac perfusion does not remove extravas-
cular or intravascular effector or memory T- cell popula-
tions that are adherent to endothelial cells within either 
the brain or lung, and as such removes blood- associated 
cells that have not been recruited to the tissues [12, 37]. 
Tissues were chopped into small pieces, passed through a 
10- ml syringe and incubated in HBSS containing 2% FCS 
with Collagenase D (final concentration 1 mg/ml; Sigma) 
for 45 min on a tube roller at room temperature. The re-
sultant cell suspensions were filtered through a 70- µm 
cell sieve. Brain cell suspensions were layered on a 30% 
Percoll gradient and centrifuged at 2000g for 10 min, the 
supernatant was discarded, and the cell pellet collected. 
RBCs were lysed in tissue samples by addition of RBC lys-
ing buffer (BD Biosciences) and were washed and resus-
pended in HBSS containing 2% FCS (FACS buffer). Lung 
cell suspensions were refiltered through a 70- μm cell sieve 
to remove aggregates. Absolute cell numbers were deter-
mined by microscopy using a haemocytometer, and live/
dead differentiation was performed using the trypan blue 
exclusion cell viability assay (Sigma).
Isolated leucocytes were surface stained for 20  min 
with α- mCD3 (17A2), CD8 (53- 6·7), KLRG- 1 (2F1), ICOS 
(15F9), CD127 (A7R34), CD103 (2E7), CD69 (H1.2F3), 
CD44 (IMF), CD62L (MEL- 14), CD45·1 (A20), CD45·2 
(104), PD- 1 (RMP1- 30) and LAG- 3 (C9B7W). Intracellular 
staining for GrB (GB11) and Ki67 (SolA15) was performed 
for 45 min, after treatment with Foxp3 fixation/permea-
bilization buffer (eBioscience). Dead cells were excluded 
using LIVE/DEAD® Fixable Blue Dead Cell Stain Kit (Life 
Technologies). Fluorescence minus one controls were 
used to set gates. Cells were analysed with a BD LSR II 
(Becton Dickinson) using BD FACSDiva software (Becton 
Dickinson). Data were analysed with FlowJo (Tree Star 
Inc.). All antibodies were from eBioscience, Biolegend or 
BD Biosciences.
OT- I adoptive transfer
Splenic single- cell suspensions were prepared from 
CD45·1+/+ OT- I mice and CD45·1+/− OT- I mice, as 
described above. CD8+ T cells (OT- Is) were nega-
tively selected by staining splenocytes with anti- mCD4 
(GK1·5), F4/80 (BM8), MHC- II (M5/114·15·2) and CD19 
(eBio1D3), all conjugated to phycoerythrin (PE), and 
using anti- PE conjugated midiMACS beads, according 
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to the manufacturer's instructions (Miltenyi Biotec). The 
flow through containing CD8+ T cells was collected and 
was examined by flow cytometry (cells 95% T cell receptor 
αβ+ and predominantly CD44−CD62L+). In the majority 
of experiments, 10 000 CD45·1+/− OT- I cells were adop-
tively transferred into naïve C57BL/6 mice 1 day prior to 
primary infection with PbA- OVA. In some experiments, 
10 000 CD45·1+/+ OT- I cells were adoptively transferred 
to C57BL/6 mice on approximately day 60 post- PbA- OVA 
infection prior to secondary re- infection.
Immunohistochemistry
Brains were sectioned at 10  µm on a cryostat (Leica), 
mounted on SuperFrost Plus slides (Thermo Fisher) and 
fixed with 4% paraformaldehyde for 10 min. Slides were 
washed with PBS, and non- specific binding blocked (1% 
BSA, 0·05% Tween- 20 in PBS) for 1 h, followed by over-
night incubation at 4 °C with Alexa Fluor® 647 anti- mouse 
CD45·1 (1:100, BioLegend) and PE anti- mouse CD31 
(1:100, BioLegend). Slides were then washed with PBS, 
incubated with DAPI (0·5  µg/ml) for 30  min, washed 
again with PBS and covered- slipped with ProLong Gold 
(Invitrogen). Images were captured using an Olympus 
BX63 upright microscope through CellSens Dimension 
v1·16 (Olympus).
RNA- seq and bioinformatics
The whole- brain RNA- seq database of PbA chemotherapy 
utilized in this study and the mRNA quality control, se-
quencing, mapping and the bioinformatics analysis have 
previously been described [24], Array Express accession 
no. E- MTAB- 6474. Briefly, genes of interest were identi-
fied by pairwise comparisons between d0 samples and all 
other groups (< or >1·5 fold change and q value ≤0·05). For 
time course visualization, gene expression in each group 
was normalized to the d0 average. Gene ontology (GO) 
enrichment analysis on the differentially expressed gene 
lists was performed using The Gene Ontology Resource 
(powered by Panther). Gene network analysis on the dif-
ferentially expressed gene lists was performed using IPA.
Statistical analysis
The distribution of the data was analysed using the 
Shapiro– Wilk test. For two group comparisons, statisti-
cal significance was determined using an unpaired two- 
tailed t test (for parametric data) or the Mann– Whitney 
U test (for non- parametric data). For three or more group 
comparisons, statistical significance was determined 
using a one- way ANOVA, with Tukey post hoc analysis, 
or a Kruskal– Wallis test, with Dunn post hoc analysis, for 
parametric and non- parametric data, respectively. Results 
were considered as significantly different when p < 0·05.
RESULTS
Parasite- specific CD8+ T cells persist in 
different tissues including the brain post- 
ECM
CD8+ T- cell migration to the brain is a signature of ECM 
[5, 6] but whether CD8+ T cells persist within the brain 
long term and at a comparable level to other tissue sites 
following antimalarial drug treatment (ACT) is unknown. 
To investigate this, we adoptively transferred OT- I cells 
into mice prior to infection with PbA- OVA parasites and 
administered combined artesunate and chloroquine ACT 
on day 6 post- infection, when mice showed signs of pro-
dromal ECM (experimental schematic shown in Figure 
1a). Antimalarial drug- treated mice developed significant 
cerebral pathology, including blood– brain barrier break-
down, haemorrhage and axonal injury (as shown in [24]); 
however, the majority (80%) of drug- treated mice rapidly 
recovered by day 8 of infection and cleared patent periph-
eral parasites by day 10 (as shown in [24]).
As expected, the numbers of activated OT- I CD44+ 
cells (representative dot plots showing identification in 
Figure 1b and gating strategy in Figure S1A) peaked in 
the brain immediately post- drug treatment on day 7 of 
infection (Figure 1c). The numbers of intracerebral OT- I 
CD44+ cells in the brains of drug- treated mice on day 7 
of infection were significantly lower than in non- drug- 
treated mice experiencing fatal ECM, whereas the num-
ber of splenic OT- I CD44+ cells on day 7 of infection was 
not significantly affected by drug treatment (Figure S1B). 
Therefore, antimalarial drug administration reduced but 
did not completely abrogate OT- I CD44+ cell migration to 
and accumulation in the brain. The numbers of intracere-
bral OT- I CD44+ cells subsequently declined rapidly from 
the day 7 peak of response (Figure 1c); although signifi-
cantly increased numbers of OT- I cells were maintained 
within the brain on day 60 p.i. (compared with numbers in 
naïve mice), numbers were very low (Figure 1d). A similar 
trend in OT- I CD44+ expansion and extreme contraction 
was observed in the lung (Figure 1e- g), a comparator non- 
lymphoid organ that experiences T cell- mediated immu-
nopathology during P. berghei infection [38, 39]. The OT- I 
CD44+ cell response peaked later on day 14 post- infection 
in the spleen, the major site of T- cell priming and the dom-
inant organ for effector T- cell responses during malaria 
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[40], compared with the lung and brain and, as expected, 
a large OT- I CD44+ cell population was maintained in the 
spleen on day 60 pi (Figure 1h– j). Overall, these data show 
that memory OT- I CD44+ cells are retained in the brain as 
well as the lung and spleen long- term post- ECM.
Parasite- specific CD8+ T cells exhibit a 
distinct memory phenotype in the brain 
post- ECM
Memory T- cell responses are frequently heterogeneous, 
displaying varying phenotypic and functional character-
istics within differing tissues, which can relate to T- cell 
adaptation to local environmental conditions and cellular 
migratory (circulatory vs. tissue- resident) patterns [41, 
42]. For example, memory T cells in the brain can have 
distinct phenotypic and functional profiles compared with 
memory T cells in other tissues [27, 29]. Consequently, we 
investigated whether the memory OT- I cells retained in 
the brain post- PbA- OVA infection were comparable or 
different from the memory OT- I cells in the spleen and 
lung.
The functionality of the OT- I cells in the spleen, lung 
and brain was comparable immediately post- treatment 
of ECM on day 7 of PbA- OVA infection, as measured by 
GrB and Ki67 expression (Figure 2a,b). The expression of 
both GrB and Ki67 on OT- I cells (which were uniformly 
CD44hi) then declined rapidly and at a similar rate in the 
spleen, lung and brain, with minimal expression at day 
60 post- infection (Figure 2a,b). Thus, memory OT- I cells 
did not maintain an effector state or continued prolifer-
ation specifically in one tissue site post- PbA- OVA infec-
tion. Nevertheless, despite equivalent starting phenotypes 
F I G U R E  1  Antigen- specific CD8+ T cells persist in various tissues, including the brain, post- ECM. 10 000 naïve CD45·1+OT- I cells were 
adoptively transferred (i.v.) into CD45·2+C57BL/6 mice 1 day prior to infection with 104 PbA- OVA pRBCs. The mice were treated (i.p.) with 
antimalarial drugs (artesunate (30 mg/kg) and chloroquine (30 mg/kg)) when they exhibited signs of ECM. (a) Schematic of the experiment. 
Brain, lungs and the spleen were removed on various days preceding and post- PbA- OVA infection. (b, e, h) Representative histograms 
showing the identification of CD45·1+ OT- I cells in the different organs. (c, f, i) The numbers of CD44+OT- I cells in the tissues over the 
course of the experiment and (d, g, j) specifically on day 60 post- infection compared with naïve mice. Results are from one experiment 
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in the different organs on day 7 of PbA- OVA infection, 
the OT- I cells exhibited increasingly segregated char-
acteristics in the brain, lung and spleen at later time 
points post- PbA- OVA infection (Figure 2c– f). On day 60 
post- infection, OT- I cells within the brain were primar-
ily CD69+CD103−KLRG- 1− and CD62L−, whereas OT- I 
cells within the lung were CD69– CD103– KLRG- 1+ and 
CD62L− and OT- I cells within the spleen were predomi-
nantly CD69– CD103−KLRG- 1− and CD62L+ (Figure 2c– f). 
Therefore, memory OT- I cells that persisted in the brain, 
lung and spleen post- PbA- OVA could be discriminated by 
the expression of CD69, KRLG- 1 and CD62L, respectively. 
When we sub- characterized the memory OT- I cells into 
canonical central memory (Tcm: CD44+CD62L+CD127+), 
effector memory (Tem: CD44+CD62L−CD127+), CD69+- 
resident memory (CD69+CD103−Trm: CD44+CD62 
L−CD127+CD69+CD103−), CD103+- resident memory 
(CD103+Trm: CD44+CD62L−CD127+CD103+CD69+), 
effector (Te: CD44+CD62L−CD127−), terminally differ-
entiated effector (TdTe: CD44+CD62L−CD127−KLRG- 1+) 
effector/memory subsets (gating within spleen as shown 
in Figure S2), memory OT- I cells in the brain primar-
ily matched the phenotype of CD69+CD103− Trm cells, 
within the lung the OT- I cells were predominantly Tem 
cells and TdTe, and in the spleen the majority of OT- I cells 
were Tcm cells (Figure 2g).
Interestingly, the graded expression of T- bet has been 
shown to control the diversification of effector and mem-
ory T- cell subsets [43]. Whilst OT- I cells expressed high 
levels of T- bet in the spleen, lung and brain on day 7 of 
PbA- OVA infection, with highest expression by cells in the 
brain, by day 60 post- infection memory OT- I cells within 
the brain expressed significantly lower levels of T- bet than 
memory OT- I cells in the spleen and lung (Figure 2h,i). 
The distinct specification of the OT- I cells within the 
lung and brain (two contrasting non- lymphoid tissues) 
F I G U R E  2  Memory OT- I cells exhibit tissue- specific signatures post- ECM. 10 000 naïve CD45·1+OT- I cells were adoptively transferred 
(i.v.) into CD45·2+C57BL/6 mice 1 day prior to infection with 104 PbA- OVA pRBCs. The mice were treated (i.p.) with antimalarial drugs 
(artesunate (30 mg/kg) and chloroquine (30 mg/kg)) when they exhibited signs of ECM. Representative histograms and proportions of 
CD44+OT- I cells expressing (a) GrB, (b) Ki67, (c) CD69, (d) CD103, (e) KLRG- 1 and (f) CD62L within the spleen, lung and brain post- ECM 
(FMO from spleen). (g) The subdivision of the CD44+OT- I cell populations into canonical effector/memory T cell subsets within the spleen, 
lung and brain on day 60 post- infection. (h, i) Representative histograms and MFI of OT- I cells expressing T- bet in the spleen, lung and 
brain on day 7 and day 55 post- infection (FMO control from spleen). Results are combined from two independent experiments. Results are 
the mean ± SEM of the group (with n = 5– 6 per group/experiment). (a, c, e) Kruskal– Wallis test with Dunn's post hoc * spleen versus brain; 
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post- PbA- OVA infection is, therefore, potentially cor-
related with the level of T- bet.
Consequently, these data suggest that different signals 
may impact on memory CD8+ T cells within discrete tis-
sues post- clearance of blood- stage PbA infection, shaping 
their diversification and regulating their maintenance.
The compartmentalization and 
identity of memory OT- I cells within the 
brain following resolution of ECM
Canonical Trm cells are typically found in the paren-
chyma of tissues (reviewed [44, 45]). Thus, to examine 
whether the CD69+CD103− memory OT- I cells within 
the brain post- ECM were genuine Trm cells, we quali-
tatively assessed their compartmentalization. Consistent 
with previous reports [4, 10, 20, 46], the majority of OT- I 
cells within the brain (not including the leptomeninges 
regions, which were not assessed in this study) on day 7 
post- PbA- OVA infection were intravascular within small 
brain capillaries and larger calibre vessels (Figure 3a). 
Thus, when taken together with previous studies [4, 10, 
20, 46], activated antigen- specific CD8+ T cells do not 
appear to enter the brain parenchyma in high numbers 
during ECM. Interestingly, despite the subsequent differ-
ences in memory phenotype post- ECM, OT- I cells within 
the lung on day 7 post- PbA- OVA infection also appeared 
vascular- associated, within small alveolar capillaries 
(Figure 3b).
Unfortunately, as the total numbers of memory OT- I 
cells were very low within the brain and lung on day 
60 post- infection, we were unable to accurately anal-
yse their location by histology. Instead, to investigate 
whether the memory OT- I cells maintained an intravas-
cular location within the brain and lung on day 60 post- 
ECM, we administered anti- CD45- FITC i.v. for 3  min, 
which labels all intravascular (circulating and adherent) 
cells [35]. Although congestion and extensive occlusion 
of the cerebrovasculature are hallmarks of ECM (which 
may reduce the accuracy of this intravascular labelling 
approach during the established syndrome), vascular 
obstruction is cleared within the brain by day 14 post- 
infection (results not shown). Thus, it is an accurate ap-
proach to analyse the compartmentalization of memory 
OT- I cells on day 60 post- infection. Whilst 40% of OT- I 
cells in the spleen stained with i.v. administered anti- 
CD45- FITC (were CD45 IV+), OT- I cells within the lung 
were uniformly CD45 IV+. Conversely, OT- I cells within 
the brain were almost exclusively CD45 IV− (Figure 
3c,d). In the spleen, Tcm cells exhibited a lower trend 
in CD45 IV staining than Te and TdTe subsets, which 
likely reflected white pulp and red pulp compartmental-
ization of the splenic OT- I populations, whereas in the 
lung all Tem, Te and TdTe subsets were equally CD45 IV+ 
(Figure S3A,B). Notably, within the brain the Tem, Te, 
CD69+CD103− Trm and CD103+ Trm OT- I cell subsets 
were equivalently and almost entirely CD45 IV− (Figure 
S3A,B). Thus, OT- I cells appear to relocate from a prin-
cipally luminal to an extravascular location within the 
brain post- ECM, and this is independent of their CD69+ 
and CD103+ phenotype.
To further address the identity of the extravascular 
memory CD8+ T cell subsets within the brain post- ECM, 
we administered anti- CD8 mAbs (clone 53- 6·72) via i.p. in-
jection to mice for 2 days immediately prior to secondary 
infection (on day 60 p.i.). It has previously been shown that 
genuine tissue- resident/non- circulating memory CD8+ T 
cells, including those in the CNS, are not accessible to and 
are not depleted by systemic anti- CD8 mAb administration 
[26, 32, 47]. However, all Tem, Te, CD69+CD103− Trm and 
CD69+CD103+ Trm OT- I cell subsets in the brain on day 
60 p.i. were targeted in vivo by the administered anti- CD8 
mAb (as shown by the ability of in vivo administered 
53– 6·72 anti- CD8mAbs to inhibit the ex vivo labelling of 
CD45·1+OT- I cells with fluorescently conjugated 53.6.72 
clone anti- CD8mAbs; Figure 3e,f). These data, therefore, 
may suggest that the CD69+OT- I cells in the brain may not 
be true resident memory T cells. As expected, in vivo ad-
ministered anti- CD8 mAb also bound to all memory OT- I 
cells within the spleen and lung (Figure S3C).
To examine the immunological pathways that may in-
fluence the changing intravascular to extravascular posi-
tioning of the memory OT- I cells in the brain post- ECM, 
we re- analysed a whole brain RNA- seq database covering 
the time course of recovery from ECM [24]. We biasedly 
focussed on a number of key genes that have been pre-
viously shown to influence memory CD8+ T- cell mainte-
nance and residence (reviewed in [44, 45, 48– 50]). Many 
genes that influence CD8+ T- cell function and memory 
maintenance (such as those encoding pro- inflammatory 
and homeostatic cytokines and receptors, integrins, 
MHC and chemokines) were highly upregulated (>1·5 
fold change and q value ≤0·05) in the brain during ECM 
(Figure 3g). Thus, the brain appears to have the capacity to 
shape CD8+ T- cell responses during acute PbA- OVA infec-
tion, potentially reflecting the high level of T- bet expressed 
by intracerebral OT- I cells on day 7 of infection (Figure 
2h,i). However, the expression of the immune- genes, in-
cluding the expression of adhesion and MHC- class I mol-
ecules, quickly returned to baseline (to that in naïve mice) 
by day 60 of the experiment (53  days post- treatment of 
ECM; Figure 3g). Indeed, the overall brain transcriptome 
rapidly returned to homeostasis post- PbA infection, with 
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only 16 genes (which were not enriched within any GO 
pathways) differentially expressed in the brains on day 60 
post- infection (compared with brains from naïve mice; 
Figure 3h).
Taken together, these data indicate that brain inflam-
mation is rapidly resolved post- ECM and that this cor-
responds with the changed compartmentalization of 
intracerebral OT- I cells post- infection. However, it is un-
clear whether extravascular OT- I cells within the brain 
post- ECM are genuine Trm cells.
Memory CD8+ T cells are highly 
pathogenic and are recruited to the brain 
during secondary PbA- OVA infection
Memory OT- I cells clearly persisted in/circulated be-
tween different tissues (most prominently in the spleen, 
the dominant secondary lymphoid organ during blood- 
stage malaria [40]), post- PbA- OVA infection, suggest-
ing the cells may influence the course of challenge 
PbA- OVA infections. However, it has previously been 
F I G U R E  3  Memory OT- I cell compartmentalization changes within the brain as neuroinflammation is resolved post- ECM. 10 000 naïve 
CD45·1+OT- I cells were adoptively transferred (i.v.) into CD45·2+C57BL/6 mice 1 day prior to infection with 104 PbA- OVA pRBCs. The mice 
were treated (i.p.) with antimalarial drugs (artesunate (30 mg/kg) and chloroquine (30 mg/kg)) when they exhibited signs of ECM on day 6 
of infection. (a, b) Immunofluorescence staining showing location of OT- I cells in (a) brain cortex and (b) lung on day 7 of infection. Mice 
were administered (i.v.) with 3 μg anti- CD45- FITC mAbs for 3 min on day 60 p.i., before tissues were removed (following intracardial whole- 
body perfusion with PBS). (c) Representative histograms showing and (d) calculated percentages of CD45·1+ OT- I cells labelled with anti- 
CD45- FITC (CD45 IV+) in the spleen, lung and brain (c, compared with control non- mAb injected mice). Mice were administered (i.p.) with 
250 μg anti- CD8 (clone 53– 6·72) or isotype control mAbs for two consecutive days on day 60 p.i., and tissues were removed the following day 
(day 62) for analysis. (e) Representative dot plots showing capacity to ex vivo label brain CD45·1+ OT- I cells from anti- CD8 mAb and isotype 
control mAb treated mice with fluorophore- conjugated anti- CD8 (53– 6·72) mAbs. (f). Representative histograms showing ex vivo labelling 
of gated brain effector and memory CD45·1+OT- I subsets from anti- CD8 mAb and isotype control mAb treated mice with fluorophore- 
conjugated anti- CD8 (53– 6·72) mAbs. Brains were removed on indicated days during PbA infection and after antimalarial drug treatment 
and RNA- seq was performed. (g) Heat maps showing the expression kinetics of selected T- cell relevant genes in the brain during the course 
of the experiment. (h) Venn diagram contrasting the numbers of genes differentially expressed (< or >1·5- fold change and q value ≤0·05) 
in brains on day 7 and day 60 post- infection, compared with expression in naïve mice. (a, b) Representative images from 3 mice, with 4– 8 
fields of view captured per animal. (d) Results are combined from two independent experiments. Results are the mean ± SEM of the group 
(n = 3– 4 per group/experiment). One- way ANOVA with Tukey's post hoc test * spleen versus brain; # lung versus brain; $ spleen versus 
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proposed that memory CD8+ T- cell reactivation is signifi-
cantly inhibited during blood- stage PbA infection due to 
strong co- inhibitory receptor- mediated repression [51]. 
Consequently, to specifically investigate the reactiva-
tion characteristics of the in vivo generated memory OT- I 
cells during a second challenge blood- stage PbA- OVA 
infection, we re- infected previously infected mice with 
PbA- OVA (re- infection performed >30  days post- ACT 
clearance of primary PbA- OVA infection parasitaemia: 
experimental schematic shown in Figure 4a). Re- infected 
mice developed ECM with accelerated kinetics during 
secondary PbA- OVA infection, compared with mice expe-
riencing a first infection (Figure 4b,c).
Significantly increased numbers of memory- derived 
OT- I cells (2° effector OT- I cells) were observed within the 
spleen during a secondary challenge infection than newly 
activated effector OT- I cells (1° effector OT- I cells) within 
the spleen during a first primary infection (examined at 
the time of ECM development to ensure analysis of maxi-
mal activation of OT- I cells during each infection, D6 ver-
sus D7, respectively; Figure 4d). Moreover, at the time of 
late- stage ECM (the peak of T- cell migration during PbA 
infection), comparable numbers of 2° effector OT- I and 1° 
effector OT- I cells were observed within the brain during 
secondary and primary PbA- OVA infection, respectively 
(Figure 4e). These data, therefore, show that memory- 
derived CD8+ T cells are present at high numbers during a 
secondary PbA- OVA infection. The precursor numbers of 
memory OT- I cells were, however, significantly higher in 
previously infected mice than the 10 000 naïve OT- I cells 
transferred into uninfected mice (for example as shown 
in Figure 1j). Consequently, the relative expansion of 2° 
effector OT- I cells during secondary infection (calculated 
by dividing the numbers of 2° effector OT- I cells on day 6 
of secondary infection by the number of primary memory 
OT- I cells in mice at point of re- infection) was significantly 
lower in both the spleen and brain compared with 1° effec-
tor OT- I cells during a first primary infection (calculated 
by dividing the numbers of 1° effector OT- I cells on day 
7 of infection by number of naïve transferred OT- I cells 
at point of primary infection; Figure 4f,g). Thus, memory 
OT- I cells may have a proliferative/survival defect upon 
activation compared with naïve OT- I cells during PbA- 
OVA infection. Despite this, the activation and function 
of memory- derived 2° effector OT- I cells in the spleen and 
brain during secondary PbA- OVA infection was compa-
rable to 1° effector OT- I cells during a primary infection, 
with memory- derived 2° effector OT- I cells and 1° effector 
OT- I cells exhibiting very high levels of GrB (Figure 4h,i). 
Indeed, of the markers examined, 2° effector OT- I cells 
and 1° effector OT- I cells differed only in ICOS expression, 
which was higher on 1° effector OT- I cells during primary 
PbA- OVA infection (Figure 4h,i). 2° effector OT- I cells did 
not have higher expression of co- inhibitory molecules, 
such as PD- 1, during a secondary infection compared 
with 1° effector OT- I cells during a primary infection, 
in either the spleen or brain (Figure 4h,i). Therefore, in 
vivo generated antigen- specific memory CD8+ T cells are 
highly inflammatory, do not exhibit an activation defect 
and competently accumulate within the brain, during a 
secondary challenge PbA infection.
Memory- derived T cells dominate the 
parasite- specific CD8+ T- cell response 
during secondary PbA- OVA infection
Memory OT- I cells clearly reactivated and memory- 
derived OT- I cells accumulated within the brain during 
a secondary challenge PbA- OVA infection, suggesting a 
major role for the memory CD8+ T cells in ECM pathol-
ogy during secondary infection. However, the antigen- 
specific CD8+ T- cell response during a second challenge 
infection can be comprised of both reactivating memory 
cells (2° effector), as well as newly primed (1° effector) T 
cells recruited to the response [52]. Therefore, to investi-
gate the relative contribution of 1° effector CD8+ T cells to 
ECM development during secondary PbA- OVA infection 
we set up a mixed congenic OT- I cell adoptive transfer 
model where we could differentiate memory cell- derived 
2° effector OT- I cells (CD45·1+CD45·2+) compared with 
1° effector OT- I cells (CD45·1+CD45·2−) generated from 
newly transferred naïve OT- I cells (experimental sche-
matic in Figure 5a and gating shown in Figure 5b). Using 
this mixed congenic system, we observed significantly 
higher numbers of 2° effector OT- I cells compared with 
1° effector OT- 1 cells during secondary PbA- OVA infec-
tion (Figure 5c). The 1° effector OT- I cells also exhibited 
significantly reduced function and terminal differentia-
tion (as measured by GrB and KLRG- 1 expression) within 
the spleen compared with the 2° effector OT- I cells dur-
ing secondary infection (Figure 5d), and compared with 
counterpart 1° effector OT- I cells generated during a first 
primary PbA- OVA infection (Figure 5e). In agreement 
with this, 1° effector OT- I cells did not accumulate in high 
numbers in the brains of mice during secondary challenge 
infection, and the 1° effector OT- I cells that did accu-
mulate exhibited significantly reduced effector function, 
as shown by GrB expression, compared with 2° effector 
OT- I cells (Figure 5f,g). Importantly, the expansion and 
activation of 1° effector OT- I cells during secondary chal-
lenge infection were still restricted even in the absence of 
pre- existing memory OT- I cells, with only a difference in 
LAG- 3 expression between 1° effector OT- I cells gener-
ated in presence or absence of pre- existing memory OT- I 
cells (Figure S4). Consistent with the observation that 
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systemically administered anti- CD8 Abs were apparently 
able to access all memory populations with the spleen, 
brain and lung post- infection (Figures 3e,f and S3C), ad-
ministration of anti- CD8 mAbs immediately prior to and 
during challenge infection significantly delayed ECM dur-
ing secondary PbA- OVA infection (Figure 5h). This sug-
gests that circulating, and potentially not resident, CD8+ T 
cells promoted ECM during secondary infection.
Collectively, these data show that 2° effector CD8+ T 
cells dominate the antigen- specific CD8+ T- cell response 
contributing to ECM development during a secondary 
challenge PbA infection. Moreover, physiological num-
bers of endogenous memory CD8+ T cells, or the immune 
environment, preclude naïve CD8+ T- cell recruitment and 
activation during secondary PbA- OVA re- infection.
Memory CD8+ T- cell responses are 
suppressed following multiple infections, 
corresponding with exposure- acquired 
resistance against ECM
Whilst memory- derived 2° effector CD8+ T cells were 
highly activated during a secondary challenge infection, 
when mice were highly susceptible to ECM, it has previ-
ously been reported that repetitive antigen stimulation 
F I G U R E  4  Memory OT- I cells undergo reactivation and form pro- inflammatory secondary effector T cells during challenge PbA- 
OVA infection. Previously infected and antimalarial drug- cured CD45·2+C57BL/6 mice (which received 10 000 CD45·1+OT- I cells prior to 
primary infection) were re- infected (>30 days) with 104 PbA- OVA pRBCs (secondary infection). Naïve age- matched CD45·2+C57BL/6 mice 
(which received 10 000 CD45·1+OT- I cells prior to infection) were infected with 104 PbA- OVA pRBCs (primary infection). (a) Experimental 
schematic. The course of primary and secondary infection showing (b) peripheral blood parasitaemia, and (c) mortality. The numbers of 
1° and 2° effector CD44+OT- I cells within the (d) spleen and (e) brain of primary and secondary infected mice, respectively, when they 
developed ECM. The fold expansion in 1° and 2° effector CD44+ OT- I cells within the (f) spleen and (g) brain during primary and secondary 
infection, respectively, calculated relative to precursor OT- I numbers. The phenotype and activation of 1° and 2° effector CD44+ OT- I 
cells OT- I cells within the (h) spleen and (i) brains of primary and secondary infected mice, respectively (FMO from spleen). Results are 
from one experiment of three independent experiments. Results are the mean ± SEM of the group (n = 4– 5 per group). (a, d– g) Unpaired 
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can lead to reprogramming of memory CD8+ T cells, 
which substantially influences their reactivation char-
acteristics during recall responses [53, 54]. Of relevance, 
we have recently shown that three cycles of infection- 
drug cure promotes resistance to ECM during a fourth 
infection, associated with dampened CD8+ T- cell ac-
tivity [23]. Consequently, we questioned whether the 
antigen- specific memory CD8+ T- cell compartment was 
remodelling following repeated PbA- OVA infections, and 
if memory CD8+ T cells exhibited repressed reactivation 
characteristics during a fourth infection, corresponding 
with resistance to ECM (experimental schematic shown 
in Figure 6a).
Similar numbers of splenic memory OT- I cells were 
maintained (35– 60 days post- drug treatment and parasite 
clearance) in mice that had experienced one or three prior 
F I G U R E  5  Memory cell- derived secondary effector T cells dominate the parasite- specific CD8+ T- cell response during challenge 
PbA infection. 10 000 naïve CD45·1+/+OT- I cells were adoptively transferred (i.v.) into CD45·2+C57BL/6 mice 1 day prior to infection 
with 104 PbA- OVA pRBCs. The mice were treated (i.p.) with antimalarial drugs (artesunate (30 mg/kg) and chloroquine (30 mg/kg)) and 
after >30 days were adoptively transferred 10 000 naïve CD45·1+/−OT- 1 cells prior to re- infection with 104 PbA- OVA pRBCs. 10 000 naïve 
CD45·1+/−OT- 1 cells were transferred to naïve CD45·2+C57BL/6 mice prior to primary infection as a control. (a) Experimental schematic. 
(b) Dot plot representing the gating strategy to identify memory cell- derived 2° effector CD45·1+/+OT- I cells and 1° effector CD45·1+/−OT- I 
cells during (top row) primary infection and (bottom row) secondary PbA- OVA infection. The (c) numbers and (d) phenotype and activation 
of 2° effector and 1° effector OT- I cells during secondary challenge infection. (e) The phenotype and activation of 1° effector OT- I cells 
during primary and secondary PbA- OVA infections. The (f) numbers of 2° effector CD45·1+/+OT- I cells and 1° effector CD45·1+/−OT- I 
cells and (g) the proportions of 2° effector OT- I cells and 1° effector OT- I cells producing GrB within the brain during secondary PbA- OVA 
infection. (h) The survival of mice undergoing secondary infection treated with anti- CD8 or control IgG mAbs (250 μg) on days −1, 1, 3, 5 
and 7 of secondary infection. Results are from one experiment of three independent experiments. Results are the mean ± SEM of the group 
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PbA- OVA infections (Figure 6b). Moreover, splenic pri-
mary memory OT- I cells (those maintained after one in-
fection) and tertiary memory OT- I cells (those maintained 
after three infections) exhibited similar phenotypes, based 
upon CD44, CD127, CD69, CD103 and GrB expression. 
Tertiary splenic memory OT- I cells did, however, express 
slightly lower levels of CD62L and KLRG- 1 (Figure 6c) 
than primary memory OT- I cells. Consequently, repetitive 
PbA- OVA challenge infections did not fundamentally 
alter the magnitude of the splenic memory OT- I cell pool, 
but led to a minor skewing of the splenic memory OT- I 
cell compartment, with an increase in relative frequencies 
of Tem cells and a decrease in frequencies of TdTe cells 
(Figure 6d).
Assessing the reactivation characteristics of the pri-
mary and tertiary memory OT- I cells (into 2° effector and 
F I G U R E  6  Repeated infection does not impact the maintenance of memory parasite- specific CD8+ T cells, but their reactivation 
is repressed following multiple infections. CD45·2+C57BL/6 mice (adoptively transferred i.v. with 10 000 CD45·1+OT- I cells prior to 
infection) underwent a single or three rounds of PbA- OVA infection (104 pRBCs i.v.) – antimalarial drug cure before being re- infected 
(>30 days post- clearance of preceding infection) with PbA- OVA (second or fourth infection). (a) Experimental schematic. (b) The numbers 
of primary memory OT- I cells and tertiary memory OT- I cells in the spleen of mice post- first and third infection, respectively (>30 days 
post- clearance of preceding infection). (c) The phenotype of primary memory and tertiary memory OT- I cells in the spleen of mice post- 
first and third infection. (d) The proportion of OT- I cells exhibiting memory T- cell subset characteristics in the spleen of mice post- first or 
third infection. The (e) numbers and (f, g) phenotype of 2° effector OT- I cells and 4° effector OT- I cells in spleen of mice during a second 
and fourth infection (days 6– 8 post- infection), respectively. The (h) numbers of 2° effector OT- I cells and 4° effector OT- I cells in the brains 
of mice during a secondary and fourth infection (days 6– 8 post- infection), respectively, and (i) proportions of 2° effector OT- I cells and 4° 
effector OT- I cells in the brain expressing GrB. (c, g) Results are from one experiment of three independent experiments. Results are the 
mean ± SEM of the group (n = 3– 10). (b, d, e, h, i) Results are combined from 2 to 3 separate experiments. Results are the mean ± SEM of 
the group (n = 3– 5 per group, experiment). (b, e) Kruskal– Wallis test with Dunn's post hoc. (h) One- way ANOVA with Tukey's post hoc test. 
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4° effector cells, respectively), we found that the numbers 
of 4° effector OT- I cells trended higher in the spleens of 
mice during a fourth infection (examined on D8 p.i. when 
age- matched primary infected mice developed ECM) com-
pared with 2° effector OT- I cells in mice during secondary 
infection (examined on day 6 when the mice developed 
ECM; Figure 6e). At these corresponding time points 
during infection, splenic 4° effector OT- I cells during a 
fourth infection exhibited significantly reduced activation 
and function, including lower ICOS and GrB, compared 
with 2° effector OT- I cells during secondary infection 
(Figure 6f,g). Thus, splenic memory OT- I cell reactivation 
was dramatically impacted by infection history in repeti-
tively infected mice. In agreement, significantly reduced 
numbers of 4° effector OT- I cells accumulated in the 
brains of mice during a fourth PbA- OVA infection than 
2° effector OT- I cells in brains of mice during a second-
ary infection, with intracerebral 4° effector OT- I cells also 
showing significantly reduced levels of GrB than intrace-
rebral 2° effector OT- I cells (Figure 6h,i). As such, these 
data show that memory OT- I cell recall effector functions 
are significantly lowered in repetitively infected mice.
DISCUSSION
In this study, we have shown that antigen- specific CD8+ T 
cells are found in various tissue sites, including the brain, 
post- drug treatment of ECM. Although activated OT- I 
cells exhibited a largely uniform phenotype and function 
in the spleen, lung and brain during primary PbA- OVA 
infection, which likely reflects the systemic nature of in-
fection and the shared splenic ontogeny of the distributed 
effector T cells [14, 40], the characteristics of the memory 
OT- I cells maintained within the discrete tissues diverged 
increasingly with time post- primary infection. This sug-
gests that the memory OT- I cell responses segregating 
within the brain, lung and spleen may be regulated locally 
by the individual tissue environments, post- clearance of 
PbA- OVA infection.
The tissue division in memory subsets within the 
spleen and lung post- primary PbA infection is consis-
tent with the established model of CD8+ T- cell memory 
whereby Tem cells persist for prolonged, but not indefinite 
lengths of time, within non- lymphoid tissues, providing 
tissue immunosurveillance, and Tcm circulate between 
secondary lymphoid tissues, undergoing rapid prolifera-
tion upon re- challenge (reviewed [43, 55]). The observed 
maintenance of KLRG- 1+ OT- I cells in the lung post- PbA- 
OVA infection was interesting, given the traditional view 
that KLRG- 1+ cells are short- lived effector T cells [56]. 
However, long- lived KLRG- 1+IL- 7Rint cells have been 
shown to form after L. monocytogenes infection [57] and 
KLRG- 1+IL- 7R+ memory cells have been shown to differ-
entiate into resident and circulating memory T cells, in-
cluding Tcm cells [58]. Nevertheless, as the KLRG- 1+ cells 
within the lung post- PbA were primarily IL- 7R– , and as 
KLRG- 1+IL- 7R–  cells have high effector function but low 
proliferative capacity [55], the impact of these KLRG- 1+ 
cells compared with traditional Tem cells for tissue protec-
tion/pathology following PbA challenge, their durability, 
and whether they are influenced by repetitive infection, 
will require further investigation.
Whilst the phenotype of the memory OT- I cells within 
the spleen and lung post- primary PbA- OVA infection were 
largely as expected, the OT- I cells within the brain exhib-
ited a surprising CD69+CD103− phenotype post- PbA- OVA 
infection. In a number of tissue sites CD69+CD103− mem-
ory CD8+ T cells have been classified as Trm cells [44, 45]. 
Indeed, CD69 is believed to control memory T- cell reten-
tion in tissues through suppressing expression of S1P1, 
protecting memory T cells from S1P- dependent egress. 
[44, 45]. As we, and others, have shown that the vast ma-
jority of CD8+ T cells recruited to the brain during ECM 
are intravascular, with large numbers of perivascular/ex-
travascular cells only seen within the leptomeninges [4, 
9, 10, 20, 46], we did not expect to identify cells matching 
the CD69+Trm phenotype specifically in the brain post- 
ECM. Nevertheless, even though OT- I cells appeared to 
change from a primarily intravascular location within the 
brain during ECM to an extravascular location by day 60 
of infection (as defined by lack of labelling with i.v. ad-
ministered anti- CD45- FITC), it is unclear if the CD69+ T 
cells are bona fide Trm cells. Neither CD69 nor CD103 ex-
pression correlated with lack of CD45- FITC labelling by 
OT- I cells in the brain, with CD69−CD103− Tem and Te 
memory subsets in the brain also excluded from CD45- 
FITC i.v. labelling. Moreover, non- circulating Trm cells 
within the brain parenchyma have been shown to be re-
sistant to systemic anti- CD8 mAb administration [26, 32, 
47]. We found that the CD69+CD103−, CD69+CD103+ and 
CD69−CD103− memory OT- I cells within the brain on day 
60 p.i. were all equally accessible to and were bound by i.p. 
administered anti- CD8 mAb, similar to the memory pop-
ulations within the spleen and lung. Consequently, the 
accessibility of the memory OT- I cells within the brain to 
anti- CD8 mAb (administered i.p. over 2 days) but not anti- 
CD45- FITC (administered i.v. for only 3 min) may suggest 
that the memory CD8+ T cells within the brain post- ECM 
operate within an immunosurveillance programme and 
transit between the blood and brain extravascular spaces. 
Thus, further work will be required to fully understand the 
positioning and activities of the CD69+ and CD69− mem-
ory CD8+ T- cell subsets in the brain post- ECM. This will 
include analysing pro- inflammatory cytokine production 
by the intracerebral memory CD8+ T- cell subsets, as Trm 
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cells are characterized by rapid and high levels of IFN- γ 
production (reviewed [44, 45]). Notably, although our ob-
servation that in vivo administered anti- CD8 mAb bound 
to but did not deplete memory OT- I cells was surprising, 
our results are consistent with a recent report indicating 
that anti- CD8mAb clone 53·7.62 binds to and functionally 
inactivates CD8+ T cells (including causing downregula-
tion of the CD8 receptor), but does not promote extensive 
depletion [59]. Importantly, we and others have used the 
anti- CD8 mAb clone 53- 7·62 extensively in murine mod-
els of malaria to inhibit CD8+ T cell- mediated pathology 
[36, 38, 60]
The reasons why memory OT- I cells compartmentalize 
differently in the lung (intravascularly) and brain (extra-
vascularly) and adopt different phenotypes post- ECM is 
not immediately obvious. During established ECM, our 
results, along with that of others, suggest that CD8+ T 
cells accumulate within blood vessels and interact with 
cross- presenting endothelial cells in equivalent manner in 
the lung and brain [4, 12, 16, 38]. This would suggest that 
the OT- I cells engage with antigen— a key event in shap-
ing intra- tissue memory immune responses [28, 61]— in 
a similar way within the lung and brain during PbA- OVA 
infection. However, CD69 and KLRG- 1 expression on T 
cells is also controlled by differing signals, with CD69 ex-
pression controlled by TCR signalling, type- 1 interferon, 
IL- 33 and TNF, whereas IL- 12 and IL- 15 promote KLRG- 1 
expression ([56– 58, 61] and reviewed [44, 45]). Relating 
to this, it was notable that memory OT- I cells expressed 
higher levels of T- bet in the lung than in the brain on day 
60 of infection. Inflammation has been shown to promote 
T- bet expression in activated CD8+ T cells during viral in-
fection, which subsequently controls KLRG- 1 expression 
[56]. Consequently, this may suggest that the brain and 
the lung immunological environments differ markedly 
post- ECM, sustaining the apparent differences in OT- I 
cell compartmentalization and imprinting the observed 
tissue- specific cellular phenotypes. Although we did not 
analyse the lung transcriptome post- ECM, inflammation 
was rapidly resolved in the brain post- ECM.
Our results clearly showed that primary memory OT- I 
cell recall was, overall, extremely strong during secondary 
PbA- OVA infection. Thus, despite the slightly lower pe-
ripheral parasite burden during secondary PbA- OVA in-
fection, there was apparently sufficient available antigen to 
allow the memory- derived 2° effector CD8+ T cells to reac-
tivate. As such, our data suggest that primary memory OT- I 
cells generated after a single PbA- OVA infection are not 
intrinsically defective with limited reactivation potential, 
although they may exhibit a lower expansion capacity than 
naïve OT- I cells (with the caveat that it is difficult to ac-
curately calculate and compare the fold- change expansion 
of effector T cells from precursor naïve or memory cells in 
a tissue during different infections due to the level of ef-
fector T- cell migration that occurs and also the impact of 
environmental changes within primary and secondary in-
fection). These results, therefore, contrast with a previous 
report that in vitro generated memory OT- I cells (both Tcm 
and Tem subsets) are inhibited and are less responsive than 
naïve OT- I cells during PbA infection [51]. Indeed, our re-
sults suggest the opposite, with in vivo generated memory- 
derived 2° effector CD8+ T cells dominating the pathogenic 
CD8+ T- cell response during secondary challenge PbA in-
fection with virtually no recruitment of 1° effector CD8+ 
T cells to the immune response. The repression of naïve 
OT- I cell activation during challenge PbA- OVA infection is 
likely mediated by the pre- existing memory OVA- specific 
CD8+ T cells (endogenous and/or transferred OT- I cells). 
Indeed, antigen- specific memory CD8+ T cells can restrict 
the activation of naïve CD8+ T cells specific for the equiv-
alent antigen [52, 62]. The relative contribution of the dif-
ferent OT- I memory cell subsets in the various tissues to 
the overall 2° effector OT- I response during challenge PbA 
infection will require additional investigation.
Whilst primary memory OT- I cells had very strong 
reactivation, principally measured by GrB expression, 
during a second PbA- OVA infection, the reactivation of 
tertiary memory OT- I cells was significantly tempered 
during a fourth PbA- OVA infection, when mice are re-
sistant to ECM [23]. Although repetitive stimulation can 
alter the size of the memory T- cell compartment in other 
models [54, 63], the magnitude of the memory OT- I cell 
response was equivalent in the spleen after one or three 
PbA- OVA infections. Thus, the altered reactivation of 
tertiary memory OT- I cells during a fourth infection was 
not simply a function of increased memory T- cell num-
bers. However, in agreement with other studies showing 
that repetitive antigen stimulation can induce stepwise 
changes in the memory CD8+ T- cell compartment [52, 
53, 63], we observed a slight increase in the proportion of 
Tem OT- I cells and a small decrease in the frequencies of 
TdTe KLRG- 1+ OT- I cells (i.e. long- lived effector T cells) 
following three rounds of PbA- OVA infections. It is clear 
that different memory CD8+ T- cell populations have dif-
fering proliferative, cytokine production and cytolytic ca-
pacities upon reactivation [43, 55, 57, 58]. Thus, although 
more in- depth investigations such as single- cell RNA- 
seq or proteomics are required to confirm our analyses, 
repetitive- stimulation reprogramming or skewing of the 
maintained splenic memory OT- I cell compartment may 
contribute to the repressed reactivation of memory OT- I 
cells upon repeated PbA- OVA infections. Of relevance, 
repeated P.  falciparum infection also leads to alterations 
in the phenotype and function of CD8+ T cells in chil-
dren [64], suggesting that such a scenario may be asso-
ciated with protection against severe malarial disease in 
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humans. Nevertheless, we do not discount the possibil-
ity that variations in the inflammatory environment that 
manifest following repetitive challenge PbA infections, 
which may include differences in the APC compartment, 
parasite levels and cytokine production [23, 65, 66], may 
also contribute to the alterations in memory CD8+ T- cell 
reactivation in repeatedly PbA- infected mice. We acknowl-
edge the caveat of normalizing the days of analysis during 
second (day 6 of infection) and fourth (day 8 of infection) 
PbA- OVA infections to the timepoint of ECM develop-
ment (in the case of four times infected mice, relative to 
ECM development in control primary PbA- OVA- infected 
mice). This may have introduced temporal differences in, 
for example, time from initial TCR triggering or dynam-
ics of T- cell activation into our comparisons of the OT- I 
cells in the two infections. Nevertheless, our approach was 
necessary to analyse the peak splenic activation and sub-
sequent migratory potential of reactivated T cells to the 
brain during the respective second and fourth PbA- OVA 
infections, as maximal T- cell activation in the PbA model 
occurs concurrent with ECM development [5, 9, 36, 67].
In summary, our data emphasize the tissue- specific 
complexity of the memory CD8+ T- cell response that is 
generated following blood- stage PbA infection. This ob-
servation has significant implications for considering the 
relative contribution of specific tissue and memory cell 
subsets in influencing local and systemic antigen- specific 
CD8+ T- cell responses during challenge blood- stage PbA 
infections. Moreover, our results suggest that memory 
CD8+ T- cell reactivation during challenge PbA infections 
is not stably imprinted, but it is shaped by the number 
of infection episodes. These observations may have rele-
vance for human malaria, where GrB+ CD8+ T cells have 
recently been proposed to play a role in the pathogenesis 
of severe P. falciparum malaria [21, 22] and where the na-
ture of memory T- cell reactivation has been postulated to 
play a role in susceptibility and resistance against severe 
malaria disease [68].
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